[The use of platelet aggregation inhibitor in nephrodialysis].
D000241:Adenosine / Q000008:administration & dosage*; D001778:Blood Coagulation Disorders / Q000209:etiology / Q000517:prevention & control*; D011464:Epoprostenol / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000008:administration & dosage*; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage*; D006435:Renal Dialysis / Q000009:adverse effects*; D013927:Thrombosis / Q000517:prevention & control
D011453:Prostaglandins; D011459:Prostaglandins E, Synthetic; D006493:Heparin; D011464:Epoprostenol; D000241:Adenosine
Considerazioni sull'impiego degli antiaggreganti piastrinici nella nefrodialisi.